Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

References

• Hamblin TJ, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Maloum K, Davi F, Merle-Beral H, . Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000;96:377–379.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Gribben JG, Peterson BL, . Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437–443.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343: 1910–1916.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, . 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89: 2516–2522.
   PubMed Web of Science ®Google Scholar
• Fegan C, Robinson H, Thompson P, . Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995;9:2003–2008.
   PubMed Web of Science ®Google Scholar
• Neilson JR, Auer R, White D, . Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:1929–1932.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29:544–550.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, . Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011;29:1349–1355.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, . p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580–1589.
   PubMed Web of Science ®Google Scholar
• el Rouby S, Thomas A, Costin D, . p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82: 3452–3459.
   PubMed Web of Science ®Google Scholar
• Malcikova J, Smardova J, Rocnova L, . Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009;114:5307–5314.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Deambrogi C, . The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995–1004.
   PubMed Web of Science ®Google Scholar
• Zenz T, Krober A, Scherer K, . Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322–3329.
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Martinez P, Wade R, . Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223–2229.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, . Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799–804.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Tam C, Abruzzo LV, . Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373–380.
   PubMed Web of Science ®Google Scholar
• Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 2001;54:512–516.
   PubMed Web of Science ®Google Scholar
• Schaffner C, Stilgenbauer S, Rappold GA, . Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999;94:748–753.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Weber P, Stewart G, . Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999;353:26–29.
   PubMed Web of Science ®Google Scholar
• Bullrich F, Rasio D, Kitada S, . ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999;59:24–27.
   PubMed Web of Science ®Google Scholar
• Ishibe N, Goldin LR, Caporaso NE, . ATM mutations and protein expression are not associated with familial B-CLL cases. Leuk Res 2003;27:973–975.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Stewart GS, Byrd P, . ATM mutations in sporadic lymphoid tumours. Leuk Lymphoma 2002;43:1563–1571.
   PubMed Web of Science ®Google Scholar
• Yuille MR, Condie A, Hudson CD, . ATM mutations are rare in familial chronic lymphocytic leukemia. Blood 2002;100:603–609.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Stewart GS, Fegan C, . Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002;99:300–309.
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, . Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25: 5448–5457.
   PubMed Web of Science ®Google Scholar
• Austen B, Powell JE, Alvi A, . Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106: 3175–3182.
   PubMed Web of Science ®Google Scholar
• Skowronska A, Austen B, Powell JE, . ATM germline heterozygosity does not play a role in CLL initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica 2012;97:142–146.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Teraoka S, Southey MC, . Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T > G and c.1066-6T > G (IVS10-6T > G) from the Breast Cancer Family Registry. Hum Mutat 2006;27:1122–1128.
   PubMed Web of Science ®Google Scholar
• Dork T, Bendix R, Bremer M, . Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001;61:7608–7615.
   PubMed Web of Science ®Google Scholar
• Fletcher O, Johnson N, dos Santos Silva I, . Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev 2010;19:2143–2151.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Hormazabal P, Bravo T, Blanco R, . Association of common ATM variants with familial breast cancer in a South American population. BMC Cancer 2008;8:117.
   PubMed Web of Science ®Google Scholar
• Gumy-Pause F, Wacker P, Sappino AP. ATM gene and lymphoid malignancies. Leukemia 2004;18:238–242.
   PubMed Web of Science ®Google Scholar
• Scott SP, Bendix R, Chen P, . Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA 2002;99: 925–930.
   PubMed Web of Science ®Google Scholar
• Bretsky P, Haiman CA, Gilad S, . The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 2003;12:733–738.
   PubMed Web of Science ®Google Scholar
• Broeks A, Braaf LM, Huseinovic A, . The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 2008;107:243–248.
   PubMed Web of Science ®Google Scholar
• Einarsdottir K, Rosenberg LU, Humphreys K, . Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res 2006;8:R67.
   PubMed Web of Science ®Google Scholar
• Schneider J, Illig T, Rosenberger A, . Detection of ATM gene mutations in young lung cancer patients: a population-based control study. Arch Med Res 2008;39:226–231.
   PubMed Web of Science ®Google Scholar
• Sipahimalani P, Spinelli JJ, MacArthur AC, . A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma. Int J Cancer 2007;121: 1967–1975.
   PubMed Web of Science ®Google Scholar
• Concannon P, Haile RW, Borresen-Dale AL, . Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res 2008;68:6486–6491.
   PubMed Web of Science ®Google Scholar
• Schrauder M, Frank S, Strissel PL, . Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J Cancer Res Clin Oncol 2008;134:873–882.
   PubMed Web of Science ®Google Scholar
• Rudd MF, Williams RD, Webb EL, . The predicted impact of coding single nucleotide polymorphisms database. Cancer Epidemiol Biomarkers Prev 2005;14:2598–2604.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Sherrington PD, Stewart G, . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814–822.
   PubMed Web of Science ®Google Scholar
• Lahdesmaki A, Kimby E, Duke V, . ATM mutations in B-cell chronic lymphocytic leukemia. Haematologica 2004;89:109–110.
   PubMed Web of Science ®Google Scholar
• Bevan S, Catovsky D, Marossy A, . Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia 1999;13:1497–1500.
   PubMed Web of Science ®Google Scholar